Effect of Remimazolam versus propofol on postoperative quality of recovery in patients undergoing kidney transplantation: a randomized controlled trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200065389

Enrollment

Unknown

Registered

2022-11-03

Start date

2022-11-10

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative quality of recovery

Interventions

Remimazolam Group:Remimazolam

Propofol Group:Propofol

Eligibility

Sex/Gender

All

Age

18 Years to 84 Years

Inclusion criteria

Inclusion criteria: 1. Allogeneic kidney transplant recipient; 2. Aged 18-84 years; 3. Body mass index BMI 18-28kg/m2.

Exclusion criteria

Exclusion criteria: 1. Severe neuropsychiatric disease; 2. Preoperative combined with severe respiratory or circulatory dysfunction; 3. Used benzodiazepines or opioids within one month; 4. Those with contraindications or allergy to benzodiazepines, opioids, propofol and their components; 5. Patients with difficult airways.

Design outcomes

Primary

Measure	Time frame
The quality of recovery;	—

Secondary

Measure	Time frame
SpO2;Heart rate;Mean arterial pressure;Application of vasoactive drugs;Hypoxemia;Fluctuation of blood pressure;Intraoperative awareness;Somnolence;Nausea and vomiting;Emergency delirium;Creatinine;	—

Countries

China

Contacts

Public ContactSong Wang

The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China

wangsong2258@126.com+86 15956931949

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026